Table 3.
Odds ratio (OR) and 95% confidence interval (CI) of clinical status and WWOX rs11545028 genotypic frequencies in 578 patients with prostate cancer.
| Variable | Genotypic frequencies | |||
|---|---|---|---|---|
| rs11545028 | CC (N=341) | CT+TT (N=237) | OR (95% CI) | p value |
| PSA at diagnosis (ng/mL) | ||||
| ≤ 10 | 156 (45.7 %) | 114 (48.1 %) | 1.00 | p=0.577 |
| > 10 | 185 (54.3 %) | 123 (51.9 %) | 0.910 (0.653-1.268) | |
| Pathologic Gleason grade group | ||||
| 1+2+3 | 289 (84.8%) | 194 (81.9%) | 1.00 | p=0.356 |
| 4+5 | 52 (15.2%) | 43 (18.1%) | 1.232 (0.791-1.919) | |
| Clinical T stage | ||||
| 1+2 | 298 (87.4%) | 202 (85.2%) | 1.00 | p=0.455 |
| 3+4 | 43 (12.6%) | 35 (14.8%) | 1.201 (0.743-1.942) | |
| Clinical N stage | ||||
| N0 | 333 (97.7 %) | 232 (97.9 %) | 1.00 | p=0.851 |
| N1 | 8 (2.3 %) | 5 (2.1 %) | 0.897 (0.290-2.777) | |
| Clinical M stage | ||||
| M0 | 336 (98.5 %) | 232 (97.9 %) | 1.00 | p=0.560 |
| M1 | 5 (1.5 %) | 5 (2.1 %) | 1.448 (0.415-5.059) | |
| Pathologic T stage | ||||
| 2 | 186 (54.5%) | 120 (50.6%) | 1.00 | p=0.354 |
| 3+4 | 155 (45.5%) | 117 (49.4%) | 1.170 (0.839-1.631) | |
| Pathologic N stage | ||||
| N0 | 315 (92.4%) | 214 (90.3%) | 1.00 | p=0.377 |
| N1 | 26 (7.6%) | 23 (9.7%) | 1.302 (0.724-2.343) | |
| Seminal vesicle invasion | ||||
| No | 276 (80.9%) | 175 (73.8%) | 1.00 | p=0.043* |
| Yes | 65 (19.1%) | 62 (26.2%) | 1.504 (1.012-2.236) | |
| Perineural invasion | ||||
| No | 92 (27.0%) | 63 (26.6%) | 1.00 | p=0.916 |
| Yes | 249 (73.0%) | 174 (73.4%) | 1.020 (0.702-1.484) | |
| Lymphovascular invasion | ||||
| No | 284 (83.3%) | 197 (83.1%) | 1.00 | p=0.959 |
| Yes | 57 (16.7%) | 40 (16.9%) | 1.012 (0.649-1.576) | |
| D'Amico classification | ||||
| Low/Intermediate risk | 161 (47.2%) | 118 (49.8%) | 1.00 | p=0.542 |
| High risk | 180 (52.8%) | 119 (50.2%) | 0.902 (0.647-1.257) | |
The ORs with analyzed by their 95% CIs were estimated by logistic regression models. * p value < 0.05 as statistically significant.